Health
China greenlights new mRNA vaccine targeting tumors
WestGene Biopharma plans to conduct further clinical trials to advance vaccine's application in tumor immunotherapy
Alperen Aktaş |
16.08.2024 - Update : 16.08.2024
Istanbu
ISTANBUL
China's pharmaceutical regulatory authority has approved a new mRNA vaccine designed to target Epstein-Barr virus (EBV) positive tumors for Phase I clinical trials.
Developed by WestGene Biopharma, based in Chengdu, Sichuan Province, the vaccine had earlier received approval from the US Food and Drug Administration in May, according to Chinese state-run Xinhua News.
The vaccine has also successfully completed early trials for nasopharyngeal carcinoma and lymphoma, which are among the cancers linked to EBV, a Group-I carcinogen associated with over 10 types of cancer, including gastric cancer.
WestGene Biopharma plans to conduct further clinical trials to explore the vaccine's potential in advancing tumor immunotherapy.
Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
Deputy army chief says UK troops ready to 'fight tonight' amid rising tension in Ukraine war
US, Chinese defense chiefs join southeast Asian counterparts in Laos for ASEAN annual meeting of defense ministers
Russia says it supported G20 call to end conflict in Ukraine because it was appropriately formulated
Russian president, Iraqi premier discuss situation in Middle East
International Criminal Court issues arrest warrants for Israeli Premier Netanyahu, former Defense Minister Gallant
